BETAMETHASONE SODIUM PHOSPHATE
Clinical safety rating: avoid
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
Glucocorticoid receptor agonist; modulates gene expression to suppress inflammation, immune response, and reduce capillary permeability.
| Metabolism | Hepatic via CYP3A4 (minor); primarily converted to betamethasone base by phosphatases; excreted renally. |
| Excretion | Renal: 90-95% as inactive metabolites; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 5-6 hours (plasma); biological half-life (HPA axis suppression): 24-36 hours. |
| Protein binding | 64-84% primarily bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue distribution including penetration into cerebrospinal fluid and breast milk. |
| Bioavailability | Oral: 80-90%, but with significant first-pass metabolism; IM: 80-100%; IV: 100%. |
| Onset of Action | Intravenous: within 1 hour; intramuscular: 2-4 hours; oral: 4-6 hours. |
| Duration of Action | IV/IM: 24-48 hours (HPA suppression); oral: 12-24 hours (single dose); clinical effect may persist longer with chronic use. |
| Molecular Weight | 516.41 Da (as betamethasone sodium phosphate, C22H28FNa2O8P) |
0.5-9 mg/day IV or IM in divided doses every 12-24 hours; acute conditions may require 4-8 mg IV initially.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment; use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%. |
| Pediatric use | 0.02-0.3 mg/kg/day IV or IM in divided doses every 6-12 hours, not to exceed 12 mg/day. |
| Geriatric use | Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, and fluid retention; consider bone mineral density monitoring. |
| 1st trimester | Corticosteroids are generally avoided in the first trimester unless the benefit outweighs risk; studies suggest increased risk of oral clefts. Use only for life-threatening conditions. |
| 2nd trimester | Use if clearly needed; animal studies show fetal risk but human data limited. Minimize dose and duration. |
| 3rd trimester | Used for fetal lung maturation in preterm labor; chronic use may cause adrenal suppression in neonate. |
Clinical note
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
| FDA category | Positive |
| Placental transfer | Betamethasone readily crosses the placenta; the phosphate ester is hydrolyzed to active betamethasone. Fetal concentrations are approximately 33% of maternal concentrations. |
■ FDA Black Box Warning
None (no FDA boxed warning for betamethasone sodium phosphate specifically; injectable corticosteroids may have warnings related to epidural administration).
| Common Effects | Hyperglycemia |
| Serious Effects |
Systemic fungal infectionHypersensitivity to betamethasone or any componentAdministration of live or live-attenuated vaccines (due to immunosuppression)Intrathecal route (not indicated for betamethasone sodium phosphate)
| Precautions | Immunosuppression and increased infection risk; adrenal suppression with prolonged use; osteoporosis with long-term use; hyperglycemia; cataracts/glaucoma; growth retardation in children; neuropsychiatric effects; HPA axis suppression. |
| Food/Dietary | Concomitant intake of grapefruit or grapefruit juice may increase betamethasone concentrations due to CYP3A4 inhibition, potentially amplifying steroid effects and toxicity. High-salt foods should be limited to reduce risk of fluid retention and hypertension. Corticosteroids may increase potassium loss; patients should avoid excessive consumption of licorice (which can worsen hypokalemia) and consider potassium-rich foods (bananas, oranges) if hypokalemia occurs. Alcohol may exacerbate gastric mucosal irritation, increasing risk of peptic ulcer disease. |
Loading safety data…
| Breastfeeding | Betamethasone is excreted into breast milk in low concentrations; with maternal doses up to 10 mg/day, amounts are unlikely to cause adverse effects in the infant. Caution with long-term high-dose therapy due to potential growth suppression. |
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | Betamethasone sodium phosphate is a category C drug in the first trimester and category D in the second and third trimesters. First trimester: Cleft palate (increased risk with first trimester exposure based on animal data; human data limited). Second/third trimester: Fetal adrenal suppression, growth restriction, decreased birth weight; used therapeutically for fetal lung maturation (benefit-risk). |
| Fetal Monitoring | Maternal: Blood glucose (hyperglycemia), blood pressure, signs of adrenal suppression, fluid/electrolyte balance. Fetal: Ultrasound for growth, amniotic fluid volume; fetal heart rate monitoring if used tocolytically. Neonatal: Adrenal function, growth parameters, signs of hypoglycemia. |
| Fertility Effects | Betamethasone may cause menstrual irregularities and inhibition of gonadotropin secretion, potentially impairing fertility. Reversible upon discontinuation. |
| Clinical Pearls | Because betamethasone sodium phosphate is a water-soluble phosphate ester, it provides rapid onset of action when given intravenously, making it suitable for acute conditions like status asthmaticus or anaphylaxis. It has a long half-life (36-54 hours) and is preferred for its minimal mineralocorticoid activity, reducing risk of sodium retention and edema. With intra-articular injection, it can cause local crystal-induced synovitis. In neonates, betamethasone is used antenatally to accelerate fetal lung maturity by inducing surfactant production, and the phosphate formulation allows rapid absorption from the amniotic fluid. Beware of acute adrenal crisis upon abrupt withdrawal after prolonged use. For dermatological use, it is a high-potency corticosteroid; avoid prolonged application on intertriginous areas to reduce risk of striae. |
| Patient Advice | Do not stop taking this medication suddenly without consulting your doctor, as it may cause withdrawal symptoms such as fatigue, muscle weakness, or low blood pressure. · If you are using betamethasone sodium phosphate injection, inform your healthcare provider immediately if you experience signs of infection (fever, sore throat) or allergic reaction (rash, difficulty breathing). · For topical or intra-articular use, do not cover the area with bandages or dressings unless directed, as this can increase absorption and side effects. · Avoid live vaccines (e.g., MMR, varicella) while on this medication, as it can weaken your immune response. · Take with food or milk to reduce gastrointestinal irritation if taking orally. · Monitor for signs of hyperglycemia (increased thirst, frequent urination) if you have diabetes, as corticosteroids can raise blood sugar. |